Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
July 09, 2013 -- Text Expert analyst opinion on the impact of AMNOG, Germany’s Pharmaceutical Market Reorganization Act, on future diabetic therapies and leading diabetes players including Bristol-Myers Squibb/AstraZeneca, Novartis, and Merck & Co. Bristol-Myers Squibb/AstraZeneca, Novartis, and Merck & Co could soon have to drop the prices of their dipeptidyl peptidase-IV (DPP-IV) inhibitors Onglyza (saxagliptin), Galvus (vildagliptin), and Januvia (sitagliptin) in Germany if health technology appraisal bodies there remain less than impressed. The products are undergoing the first retrospective review under Germany’s tough Pharmaceutical Market Reorganization Act (AMNOG; Arzneimittelmarktneuordungsgesetz) pricing and reimbursement system, and the Institute for Quality and Efficiency in Healthcare (IQWiG; Institut für Qualitat und Wirtschaftlichkeit im Gesundheitswesen) released its preliminary findings on 1 July 2013.
Pricing in Germany matters not only because it is one of Europe’s biggest markets, but also because a number of other European countries reference prices there. Therefore, price cuts in Germany could eventually lead to reductions elsewhere and impact significantly on company revenues.
Help employers find you! Check out all the jobs and post your resume.
